A Combination of PKC412 and 5-azacytidine for the Treatment of Patients with Refractory, Relapsed or Untreated Acute Leukemia and Myelodysplastic Syndrome (MDS)

Trial Profile

A Combination of PKC412 and 5-azacytidine for the Treatment of Patients with Refractory, Relapsed or Untreated Acute Leukemia and Myelodysplastic Syndrome (MDS)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Midostaurin (Primary) ; Azacitidine; Azacitidine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 27 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2016 to 1 Mar 2017.
    • 27 Feb 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top